Cargando…
Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia
Recent advances in our understanding of the molecular mechanisms underlying hypereosinophilia have led to the development of a ‘molecular’ classification of myeloproliferative disorders with eosinophilia. The revised 2008 World Health Organization classification of myeloid neoplasms included a new c...
Autores principales: | Havelange, Violaine, Demoulin, Jean-Baptiste |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747024/ https://www.ncbi.nlm.nih.gov/pubmed/23976869 http://dx.doi.org/10.2147/JBM.S33142 |
Ejemplares similares
-
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned
por: Pinilla-Ibarz, Javier, et al.
Publicado: (2016) -
Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies
por: Medves, Sandrine, et al.
Publicado: (2012) -
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
por: Mesa, Ruben A
Publicado: (2007) -
MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin
por: Bollaert, Emeline, et al.
Publicado: (2021) -
Dialysis-induced hypereosinophilia in the ICU
por: Desnos, Cyrielle, et al.
Publicado: (2022)